GlassScriptPhysician profile
Robert L Buzard
NPI 1205814910
$7,707.15
in general payments reported to CMS, 2019-2025
41 companies · $761 in 2025
The $761 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $865 · 2021: $1,182 · 2022: $1,348 · 2023: $1,703 · 2024: $1,496 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,959.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,812.35 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $716.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $495.68 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $492.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $441.20 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Teva Pharmaceuticals USA, INC. | $398.06 | 2020-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Amgen INC. | $384.21 | 2019-2024 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $354.10 | 2022-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $330.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.47 | 2019-2023 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Mylan Specialty L.P. | $218.49 | 2020-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $188.82 | 2020-2025 | Gardasil 9, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $163.44 | 2020-2022 | |
| Astellas Pharma US INC | $156.35 | 2019-2025 | Veozah |
| Nevro Corp. | $106.38 | 2021-2023 | Senza |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Buzard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.